Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Feb;50(1):83-86.
doi: 10.1016/j.medmal.2019.10.002. Epub 2019 Nov 3.

Subcutaneous teicoplanin in staphylococcal bone and joint infections

A L Destrem  1 , F Valour  2 , C Ronde-Ousteau  3 , J Gaudias  3 , O Rogeaux  4 , T Ferry  2 , E Forestier  4
Affiliations
Multicenter Study

Subcutaneous teicoplanin in staphylococcal bone and joint infections

A L Destrem et al. Med Mal Infect. 2020 Feb.

Abstract

Objective: We aimed to describe the use of subcutaneous teicoplanin as an alternative for the treatment of staphylococcal bone and joint infections.

Methods: A retrospective multicentric cohort (2002-2015) was conducted with patients receiving subcutaneous teicoplanin for a staphylococcal bone and joint infection.

Results: Forty patients were assessed. A median loading dose of 9.4 mg/kg/12h (IQR, 6.1-13.1) was administered to 35 patients, subcutaneously for 18 of them. Thirteen of these patients received three injections per week. No excess risk of failure was identified. The trough level was not significantly different between the various routes (p=0.462), and was significantly higher if the loading dose was≥9 mg/kg/injection (p<10-3).

Conclusion: The use of subcutaneous teicoplanin seems to be acceptable as an alternative to other routes of administration for antibiotics.

Keywords: Bone and joint infection; Infections ostéoarticulaires; Subcutaneous administration; Teicoplanin; Téicoplanine; Voie sous-cutanée.

PubMed Disclaimer

Publication types

LinkOut - more resources